CN101065493A - 在酮酸存在下的酶促反应 - Google Patents
在酮酸存在下的酶促反应 Download PDFInfo
- Publication number
- CN101065493A CN101065493A CNA2005800401631A CN200580040163A CN101065493A CN 101065493 A CN101065493 A CN 101065493A CN A2005800401631 A CNA2005800401631 A CN A2005800401631A CN 200580040163 A CN200580040163 A CN 200580040163A CN 101065493 A CN101065493 A CN 101065493A
- Authority
- CN
- China
- Prior art keywords
- salt
- increased response
- acid
- amidated
- ketoacid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006911 enzymatic reaction Methods 0.000 title abstract description 6
- 150000004715 keto acids Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 125000001151 peptidyl group Chemical group 0.000 claims abstract description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 21
- 150000002148 esters Chemical class 0.000 claims abstract description 21
- 229920001192 peptidylglycine Polymers 0.000 claims abstract description 20
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims abstract description 18
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims abstract description 18
- 239000004471 Glycine Substances 0.000 claims abstract description 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 10
- 102000004317 Lyases Human genes 0.000 claims abstract description 7
- 108090000856 Lyases Proteins 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 239000002879 Lewis base Substances 0.000 claims abstract description 5
- 150000007527 lewis bases Chemical class 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 65
- 230000004044 response Effects 0.000 claims description 43
- 239000002253 acid Substances 0.000 claims description 23
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 19
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 16
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 16
- 239000002243 precursor Substances 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 12
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 12
- 230000026030 halogenation Effects 0.000 claims description 10
- 238000005658 halogenation reaction Methods 0.000 claims description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000005805 hydroxylation reaction Methods 0.000 claims description 8
- 229940107700 pyruvic acid Drugs 0.000 claims description 8
- 239000008177 pharmaceutical agent Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229940054269 sodium pyruvate Drugs 0.000 claims description 6
- VTESCYNPUGSWKG-UHFFFAOYSA-N (4-tert-butylphenyl)hydrazine;hydrochloride Chemical compound [Cl-].CC(C)(C)C1=CC=C(N[NH3+])C=C1 VTESCYNPUGSWKG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 4
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 claims description 4
- 229940117360 ethyl pyruvate Drugs 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- 230000000640 hydroxylating effect Effects 0.000 claims description 4
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- ZHWLPDIRXJCEJY-UHFFFAOYSA-N alpha-hydroxyglycine Chemical compound NC(O)C(O)=O ZHWLPDIRXJCEJY-UHFFFAOYSA-N 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 abstract description 19
- 108090000790 Enzymes Proteins 0.000 abstract description 19
- 102000016938 Catalase Human genes 0.000 abstract description 12
- 108010053835 Catalase Proteins 0.000 abstract description 11
- 239000003623 enhancer Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 9
- 238000006555 catalytic reaction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108010068072 salmon calcitonin Proteins 0.000 description 9
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 238000011938 amidation process Methods 0.000 description 5
- 238000007112 amidation reaction Methods 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 5
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 5
- 239000002516 radical scavenger Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- -1 cell factor Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000002862 amidating effect Effects 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- RILPIWOPNGRASR-UHFFFAOYSA-N (2R,3S)-2-Hydroxy-3-methylpentanoic acid Natural products CCC(C)C(O)C(O)=O RILPIWOPNGRASR-UHFFFAOYSA-N 0.000 description 1
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- 239000001668 3-methyl-2-oxopentanoic acid Substances 0.000 description 1
- JVQYSWDUAOAHFM-UHFFFAOYSA-N 3-methyl-2-oxovaleric acid Chemical compound CCC(C)C(=O)C(O)=O JVQYSWDUAOAHFM-UHFFFAOYSA-N 0.000 description 1
- 239000001142 4-methyl-2-oxopentanoic acid Substances 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000058004 human PTH Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- LMKPPOCIIACDQU-UHFFFAOYSA-N phenyl 2-oxopropanoate Chemical compound CC(=O)C(=O)OC1=CC=CC=C1 LMKPPOCIIACDQU-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/17—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced ascorbate as one donor, and incorporation of one atom of oxygen (1.14.17)
- C12Y114/17003—Peptidylglycine monooxygenase (1.14.17.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y403/00—Carbon-nitrogen lyases (4.3)
- C12Y403/02—Amidine-lyases (4.3.2)
- C12Y403/02005—Peptidylamidoglycolate lyase (4.3.2.5)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
在α-酮酸/酯的存在下rhPTH(1-31)Gly32-OHα酰胺化为rhPTH(1-31)NH2 | ||||
α-酮酸/酯 | 结构 | 浓度(mM) | 转化% | 对照(没有本发明的化合物)的转化% |
丙酮酸钠 | CH3COCO2Na | 8 | 95 | 60 |
丙酮酸乙酯 | CH3COCO2CH2CH3 | 50 | 89 | 56 |
丙酮酸 | CH3COCO2H | 6 | 86a | 56a |
丙酮酸甲酯 | CH3COCO2CH3 | 50 | 86 | 58 |
苯甲酰甲酸 | C6H5COCO2H | 10 | 82 | 67 |
2-丁酮酸,钠盐 | CH3CH2COCO2Na | 16 | 96 | 60 |
3-甲基-2-氧代丁酸,钠盐 | (CH3)2CHCOCO2Na | 64 | 78 | 38 |
2-酮戊二酸,钠盐 | HO2CCH2CH2COCO2Na | 10 | 76 | 58 |
3-甲基-2-氧代戊酸,钠盐 | C2H5CH(CH3)COCO2Na | 10-150 | ≤61 | 61 |
4-甲基-2-氧代戊酸,钠盐 | (CH3)2CHCH2COCO2Na | 10-150 | <48 | 48 |
丙酮酸苯酯,钠盐 | C6H5CH2COCO2Na | 0.1-100 | <58 | 58 |
在下列条件下进行α-酰胺化:4mg/mL rhPTH(1-31)Gly32-OH、30mM MES pH[6.3-6.5]、0.5μM硫酸铜、5mM碘化钾,2mM抗坏血酸、[0-1%]乙醇和15,000U/mL PAM。所有反应均于37℃温育4小时。在类似条件下使用过氧化氢酶(黑曲霉(Aspergillus niger))作为过氧化物清除剂进行的酰胺化一般导致rhPTH(1-31)Gly32-OH向rhPTH(1-31)-NH2的大于90%转化。a=这些数据表示三份值的平均值。 |
表2rhPTH(1-34)Gly35-OH的α酰胺化 | |
试剂 | 最终浓度 |
rhPTH(1-34)Gly35-OH | 2mg/ml |
250mM MES pH6.3 | 30mM |
3mM硫酸铜 | 0.5μM |
100mM抗坏血酸钠 | 2mM |
氧 | 溶解的氧浓度维持在饱和或接近饱和。 |
400mM丙酮酸钠 | 8mM |
250mM碘化钾 | 5mM |
190标准强度乙醇 | 1% |
PAM | 30,000U/mL |
Claims (43)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63074804P | 2004-11-24 | 2004-11-24 | |
US60/630,748 | 2004-11-24 | ||
US11/285,136 | 2005-11-22 | ||
US11/285,136 US7445911B2 (en) | 2004-11-24 | 2005-11-22 | Enzymatic reactions in the presence of keto acids |
PCT/US2005/042765 WO2006058225A2 (en) | 2004-11-24 | 2005-11-23 | Enzymatic reactions in the presence of keto acids |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101065493A true CN101065493A (zh) | 2007-10-31 |
CN101065493B CN101065493B (zh) | 2011-11-16 |
Family
ID=36498563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800401631A Expired - Fee Related CN101065493B (zh) | 2004-11-24 | 2005-11-23 | 在酮酸存在下的酶促反应 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7445911B2 (zh) |
EP (1) | EP1815004A4 (zh) |
JP (1) | JP4891256B2 (zh) |
CN (1) | CN101065493B (zh) |
AU (1) | AU2005309479B2 (zh) |
CA (1) | CA2586128C (zh) |
WO (1) | WO2006058225A2 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006261909B2 (en) | 2005-06-24 | 2011-08-11 | Enteris Biopharma, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
US20080227134A9 (en) * | 2005-09-16 | 2008-09-18 | Unigene Laboratories Inc. | Glyoxylate assays and their use of inden tifying natural amidated compounds |
US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
JP5753097B2 (ja) | 2009-01-22 | 2015-07-22 | ユニジーン・ラボラトリーズ・インコーポレーテッド | 肥満の治療 |
HUE042929T2 (hu) | 2011-06-15 | 2019-07-29 | Resother Pharma Aps | Gyulladáscsökkentõ gyógyszerészeti termékek |
SI3095484T1 (en) | 2011-11-02 | 2018-08-31 | Keybioscience Ag | Calcitonin mimetics for the treatment of diseases and disorders |
MX351092B (es) | 2011-11-02 | 2017-10-02 | Keybioscience Ag | Analogos peptidicos para tratar enfermedades y trastornos. |
EP2964193B1 (en) | 2013-03-05 | 2019-12-11 | Enteris BioPharma, Inc. | Pharmaceuticals for oral delivery |
RS57152B1 (sr) | 2013-11-14 | 2018-07-31 | Keybioscience Ag | Mimetici kalcitonina za lečenje bolesti i poremećaja |
GB201500263D0 (en) | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
WO2016115082A1 (en) | 2015-01-12 | 2016-07-21 | Enteris Biopharma, Inc. | Solid oral dosage forms |
GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
GB201813678D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
GB201813677D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
GB202001024D0 (en) | 2020-01-24 | 2020-03-11 | Key Bioscience Ag | Oxyntomodulin mimetics |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
DE69114583T2 (de) | 1990-06-01 | 1996-06-13 | Japat Ltd., Basel | Peptdidylhydroxylglycine N-C Lyase und DNS dafür kodierend. |
DK1005526T3 (da) | 1997-04-16 | 2011-02-07 | Unigene Lab Inc | Direkte ekspression af peptider i kulturmedium |
US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
US8227241B2 (en) | 2004-03-12 | 2012-07-24 | Unigene Laboratories, Inc. | Bacterial host cell for the direct expression of peptides |
-
2005
- 2005-11-22 US US11/285,136 patent/US7445911B2/en active Active
- 2005-11-23 EP EP05824481A patent/EP1815004A4/en not_active Withdrawn
- 2005-11-23 AU AU2005309479A patent/AU2005309479B2/en not_active Ceased
- 2005-11-23 JP JP2007543530A patent/JP4891256B2/ja not_active Expired - Fee Related
- 2005-11-23 WO PCT/US2005/042765 patent/WO2006058225A2/en active Search and Examination
- 2005-11-23 CN CN2005800401631A patent/CN101065493B/zh not_active Expired - Fee Related
- 2005-11-23 CA CA2586128A patent/CA2586128C/en not_active Expired - Fee Related
-
2008
- 2008-09-22 US US12/284,552 patent/US8163871B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20090023892A1 (en) | 2009-01-22 |
WO2006058225A3 (en) | 2007-03-22 |
US7445911B2 (en) | 2008-11-04 |
JP4891256B2 (ja) | 2012-03-07 |
CA2586128A1 (en) | 2006-06-01 |
US20060127995A1 (en) | 2006-06-15 |
CA2586128C (en) | 2013-04-02 |
AU2005309479B2 (en) | 2010-05-27 |
WO2006058225A2 (en) | 2006-06-01 |
CN101065493B (zh) | 2011-11-16 |
US8163871B2 (en) | 2012-04-24 |
EP1815004A2 (en) | 2007-08-08 |
JP2008521404A (ja) | 2008-06-26 |
EP1815004A4 (en) | 2010-07-07 |
WO2006058225A8 (en) | 2007-06-28 |
AU2005309479A1 (en) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101065493A (zh) | 在酮酸存在下的酶促反应 | |
JP2008521404A6 (ja) | ケト酸が存在する状態での酵素反応 | |
Kumar et al. | Microbial proteases in peptide synthesis: approaches and applications | |
Khoronenkova et al. | D-amino acid oxidase: physiological role and applications | |
AU2006261909B2 (en) | Cell lines for expressing enzyme useful in the preparation of amidated products | |
Zieliński et al. | Expression and purification of recombinant human insulin from E. coli 20 strain | |
ZA200604772B (en) | Production of diphtheria toxin | |
CN102834109A (zh) | 稳定的生长激素化合物 | |
US6737407B1 (en) | Treatment of obesity | |
Ukkonen et al. | Use of slow glucose feeding as supporting carbon source in lactose autoinduction medium improves the robustness of protein expression at different aeration conditions | |
Zou et al. | Biosynthesis and biotechnological application of non-canonical amino acids: Complex and unclear | |
CN1037845C (zh) | 稳定的生物活性生长激素的制备方法 | |
Kreil | [21] Occurrence, detection, and biosynthesis of carboxy-terminal amides | |
Nomura et al. | Glycoprotein semisynthesis by chemical insertion of glycosyl asparagine using a bifunctional thioacid-mediated strategy | |
US20240043897A1 (en) | Subtilisin variants and their use | |
AU637765B2 (en) | C-terminus amidation enzyme composition, process for its preparation and its use | |
EP0669939A1 (en) | Somatotropin modifications | |
US6420520B1 (en) | Peptides and remedy for bone diseases containing the same as active ingredient | |
AU755512B2 (en) | Treatment of obesity | |
WO1991002790A1 (en) | Enzymes which participate in c-terminal amidation, and production and use thereof | |
JPH03502758A (ja) | ポリペプチド類においてノルロイシン含有量を制御するための発酵培地および方法 | |
WO2023201372A2 (en) | Papb as a bimoiety-dependent thioether installation tool | |
CN114891839A (zh) | 单胺氧化酶催化制备手性药物中间体的方法 | |
CN1372595A (zh) | 在基因重组多肽的生产中抑制副产物生成的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ENTELISI BIO-PHARMACEUTICAL CORP. Free format text: FORMER OWNER: UNIGENE LAB INC. Effective date: 20131231 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20131231 Address after: new jersey Patentee after: ENTERIS BIOPHARMA, INC. Address before: new jersey Patentee before: Unigene Lab Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111116 Termination date: 20201122 |